



Original article

Obstetric and perinatal health outcomes related to schizophrenia: A national register-based follow-up study among Finnish women born between 1965 and 1980 and their offspring



Laura Simoila^{a,*}, Erkki Isometsä^a, Mika Gissler^{b,c,d}, Jaana Suvisaari^e, Erja Halmesmäki^{f,g}, Nina Lindberg^h

^a Helsinki University and Helsinki University Hospital, Psychiatry, P.O. Box 590, 00029 HUS, Helsinki, Finland

^b National Institute for Health and Welfare, Information Services Department, Mannerheimintie 166, 00270 Helsinki, Finland

^c Research Centre for Child Psychiatry, University of Turku, Lemminkäisenkatu 3, 20520 Turku, Finland

^d Karolinska Institute, Department of Neurobiology, Care Sciences and Society, Division of Family Medicine, Alfred Nobels allé 23, 14183 Huddinge, Sweden

^e National Institute for Health and Welfare, Mental Health Unit, P.O. Box 30, 00271 Helsinki, Finland

^f Helsinki University and Helsinki University Hospital, Obstetrics and Gynecology, P.O. Box 140, 00029 HUS, Helsinki, Finland

^g Fameda-clinic, Kalevankatu 9 A, 00100 Helsinki, Finland

^h Helsinki University and Helsinki University Hospital, Forensic Psychiatry, P.O. Box 590, 00029 HUS, Helsinki, Finland

ARTICLE INFO

Article history:

Received 20 February 2018

Received in revised form 27 March 2018

Accepted 3 April 2018

Available online 4 May 2018

Keywords:

Delivery

Pregnancy

Postpartum period

Schizoaffective disorder

Schizophrenia

ABSTRACT

Background: This national register-based study assesses obstetric and perinatal health outcomes in women with schizophrenia and their offspring.

Methods: Using the Care Register for Health Care, we identified Finnish women who were born in 1965–1980 and diagnosed with schizophrenia. For each case, five age- and place-of-birth- matched controls were obtained from the Central Population Register of Finland. They were followed from the day when the disorder was diagnosed in specialized health-care (the index day) until 31.12.2013. Information related to births was obtained from the Medical Birth Register and the Register of Congenital Malformations. We focused on singleton pregnancies that led to a delivery after the index day. We restricted the analysis of deliveries in controls to those that occurred after the index day of the case. Maternal age, marital status, smoking status, sex of the newborn, and parity were used as covariates in adjusted models.

Results: We identified 1162 singleton births among women with schizophrenia and 4683 among controls. Schizophrenic women had a 1.4-fold increased risk of induction of labor, delivery by cesarean section, and delivery by elective cesarean section. Regarding offspring, the risk of premature birth and the risk of low Apgar score at 1 min (<7) were 1.6-fold, of resuscitation 2.5-fold, and of neonatal monitoring 2.1-fold higher.

Conclusions: Schizophrenia associates with some specific delivery methods, but delivery complications are rare and their prevalence does not differ from that observed among community women. Maternal schizophrenia associates with some negative perinatal health outcomes of the offspring.

© 2018 Elsevier Masson SAS. All rights reserved.

1. Introduction

De-institutionalization has enabled women with schizophrenia to be more sexually active [1] and the general fertility rate among them appears to have increased [2]. Since the 1960s, evidence has

accumulated for an association between schizophrenia and various obstetric and postpartum complications [3,4]. The first meta-analysis [5] reported that births to women with schizophrenia incur an increased risk of pregnancy and birth complications, as well as low birthweight and poor neonatal conditions of the offspring.

In a Danish population-based study [6–8], women with schizophrenia were at increased risk of delivery interventions such as surgical delivery, vaginal assisted delivery, amniotomy, and pharmacological stimulation of labor. Their offspring were at increased risk of preterm delivery, being small for gestational age,

* Corresponding author at: Psykiatriakeskus, P.O. Box 590, 00029 HUS, Helsinki, Finland.

E-mail addresses: laura.simoila@hus.fi (L. Simoila), erkki.isometsa@hus.fi (E. Isometsä), mika.gissler@thl.fi (M. Gissler), jaana.suvisaari@thl.fi (J. Suvisaari), erja.halmesmaki@kolumbus.fi (E. Halmesmäki), nina.lindberg@hus.fi (N. Lindberg).

low birth-weight, low Apgar scores, post-neonatal death, and congenital malformations as compared with newborns of unexposed mothers. A Swedish national population-based study [9] reported increased risks of preterm delivery, low birth-weight, being small for gestational age, stillbirth and infant death among newborns of women with schizophrenia. However, risk estimates were markedly reduced by controlling for maternal factors including: smoking during pregnancy, age, education, country of birth, pregnancy-induced hypertensive diseases, and parity. In an Australian population-based study [10], women with schizophrenia showed an increased risk of placental abnormality, abruptio placentae, prolonged labor, precipitate delivery, cephalopelvic disproportion, antepartum hemorrhages and fetal distress. Risks of gestational age <37 weeks, birth-weight <2500 g, 5-min Apgar score <7, time to spontaneous respiration >2 min, intubation, drug side effects, and receiving narcotic antagonists were all elevated among babies of women with schizophrenia. However, after adjustment for maternal age, marital status, Aboriginal descent, parity, plurality, and sex of the offspring, the only complications that remained significant were abruptio placentae and naloxone administration. The incidence of birth defects including congenital malformations and chromosomal anomalies was only marginally elevated, but there was a significant increase in the incidence of defects of the cardiovascular system and minor physical anomalies. In a population-based study from Israel [11], the need for induction of labor, augmentation of delivery, as well as low birth-weight (<2500 g) and congenital malformations of the offspring, were significantly increased among women with schizophrenia. No significant differences were observed in labor complications. According to a recent meta-study [12], neonates to women with schizophrenia are profiled with intrauterine growth retardation, prematurity, low Apgar scores, and congenital defects. Additionally, the postpartum period typically involves psychotic relapse and parenting difficulties. However, after adjusting for maternal age, unhealthy behaviors, length of antipsychotic treatment, maternal-fetal attachment, as well as parity, maternal schizophrenia remains predictive of only prematurity and postpartum psychosis. In a Canadian population-based study [13], infants born to women with schizophrenia were at higher risk of prematurity, as well as of being either small or large for gestational age. These findings remained significant after adjustment with maternal pre-pregnancy medical comorbidity, age, socio-economic status and parity. Further, compared with age- and parity-matched controls, women with schizophrenia required significantly more intensive hospital resources, including operative delivery and admission to the intensive care unit.

Overall, population-based studies of deliveries of women with schizophrenia are still relatively scarce. Moreover, delivery is influenced by cultural and socio-economic conditions, as well as the provision and funding of health care services. Therefore, research findings may be context-specific, and the generalizability of findings between settings, countries, and time periods is thus uncertain. The aim of this Finnish register-based population study was to investigate obstetric and perinatal health outcomes in women with schizophrenia and their newborns. As post-hoc analyses, we explored associations between maternal smoking and unwanted perinatal health outcomes of the offspring, as well as time trends related to these outcomes.

2. Materials and methods

2.1. Participants

The study sample comprised a Finnish national population of women who were born between 1.1.1965–31.12.1980 and diagnosed with schizophrenia or schizoaffective disorder (=broadly-

defined schizophrenia; here, schizophrenia) in specialized health-care at some point during the follow-up time ending 31.12.2013 (n = 5214). For each case, five controls were randomly selected from the Finnish Central Population Register, matched for age and place of birth, and who had not been diagnosed with schizophrenia, schizoaffective disorder or any other psychotic disorder by the end of the follow-up time. Other mental health disorders, such as depression or mood disorders, were allowed. The total final number of controls was 25,999 because for a few cases no control could be found due to the strict matching criteria.

2.2. Diagnoses of schizophrenia and schizoaffective disorder

The diagnoses were obtained from the Care Register for Health Care of the National Institute of Health and Welfare. In Finland, psychiatric classification according to the International Classification of Diseases – Eighth Revision (ICD-8) [14] served in clinical practice between 1969 and 1986 (schizophrenia: 295.0-6, 295.8-9; schizoaffective psychosis: 295.7). This classification was later replaced by the Diagnostic and Statistical Manual of Mental Disorders – Third Revised Version (DSM-III-R) [15], used in clinical practice between 1987 and 1995. However, the diagnoses were converted to ICD-9 [16] diagnoses, when, for example, reporting them to the Care Register for Health Care (schizophrenia: 295.0-6, 295.8-9; schizoaffective psychosis: 295.7). Since 1996, ICD-10 [17] has been used in Finland (schizophrenia: F20; schizoaffective psychosis: F25). The onset of schizophrenia was defined as the day when the disorder was diagnosed and coded in specialized health care.

2.3. Follow-up

Women were followed from the onset of the disorder until the individual moved abroad, died, or follow-up ended on 31.12.2013. The information on death or emigration was gathered from the Finnish Central Population Register. The follow-up time of schizophrenic women was 14.0 (standard deviation [SD] 6.9) years, and, respectively, of controls 14.3 (SD 6.9) years (p = .001).

2.4. Information on obstetric and perinatal health outcomes

2.4.1. The Medical Birth Register

The Medical Birth Register has been maintained by the National Institute of Health and Welfare since 1987. It covers all delivery hospitals in Finland and includes data on live births and stillbirths of fetuses with a birth-weight of at least 500 g or a gestational age of at least 22 weeks, as well as data on the mothers. Individual data collection starts from the beginning of pregnancy and ends after one week from the delivery. Data quality studies indicate that most of the register content corresponds well or satisfactorily with hospital records [18]. In this study, all pregnancies leading to singleton births during the follow-up period were included, whereas multiple pregnancies were excluded. The following variables were collected: maternal age at birth, marital status at the end of pregnancy, smoking in the beginning of pregnancy, sex of the newborn, the number of deliveries, breech presentation (recorded since 1991), induction of labor (since 1991), epidural anesthesia (since 1991), use of forceps/vacuum, asphyxia (since 1991), delivery by cesarean section, delivery by elective cesarean section (since 1991), a perinatal death, gestational birth age (by fetal ultrasound examination at the first maternity care visit), premature birth (<37 weeks' gestation), very premature birth (<28 weeks' gestation), birth-weight, low birth-weight (<2500 g), very low birth-weight (<1500 g), low Apgar score at 1 min (<7), very low Apgar score at 1 min (<4), assisted ventilation (since 1991), resuscitation (since 1991), and neonatal monitoring (since

1991). Also, the following ICD-10 diagnoses (since 2004) were studied: precipitate labor (O62.3), prolonged delivery (O63), fetal distress (O68), labor and delivery complicated by umbilical cord complications (O69), rupture of perineum (O70), postpartum hemorrhage (O72), maternal distress (O75.0), puerperal sepsis (O85), other puerperal infections (O86), puerperal venous complications (O87), obstetric embolism (O88), puerperal psychosis (F53.1), and puerperal depression (F53.0).

2.4.2. The Finnish Register of Congenital Malformations

The Finnish Register of Congenital Malformations has been maintained by the National Institute of Health and Welfare since 1963. The register contains data on congenital chromosomal and structural anomalies detected in stillborn and live born infants and fetuses as well as terminations of pregnancy due to congenital anomaly. It collects data from hospitals, health-care professionals, and cytogenetic laboratories and draws data from other nationwide registers, and the completeness and validity of this register is considered to be good. We included only major congenital anomalies, multiple anomalies and syndromes, excluding minor anomalies according to the European Surveillance of Congenital Anomalies (EUROCAT) criteria [19].

2.5. Covariates

We used maternal age, marital status (single vs. married/cohabitation), smoking status (yes/no), and parity as covariates (model 1). Then, sex of the newborn was added to the model (model 2). The distribution of these variables is presented in Table 1.

2.6. Data analysis

The analyses were performed in two ways; first, we included each woman's first singleton pregnancy, which led to a delivery after she was diagnosed with schizophrenia. Second, we included all of each woman's singleton pregnancies that led to deliveries after she was diagnosed with schizophrenia. Chi square (χ^2) test, Fisher's exact test, the independent samples *t*-test and logistic regression analysis were used. With regard to all pregnancies, in order to account for the clustering of pregnancies within mothers, logistic regression analysis was performed with the generalized estimating equation (GEE) method. Analyses were performed both unadjusted and adjusted for the covariates described above. Variables with less than 10 affected women (in the schizophrenia group, or in the control group, or in both groups) were omitted since these models were considered unstable. Findings were considered significant when the two-tailed $p < 0.05$. The odds ratios (ORs) with 95% confidence

intervals (CIs) are reported. Analyses were performed using SPSS 22.0 for Windows and SAS 9.3.

2.7. Ethical considerations

The Ethics Committee of Helsinki and Uusimaa Hospital District evaluated and approved the study plan. Permission to use the confidential register data in the study was granted by the National Institute for Health and Welfare and the Population Register Centre.

3. Results

The study focused on singleton pregnancies which led to a delivery after the index day (=the day when the disorder was coded in specialized health-care). This way, we identified 1162 singleton births among women with schizophrenia, of which 753 (64.8%) were the first births. We restricted the analysis of deliveries in controls to those that occurred after the index day of the case, which led to 4683 singleton births, of which 2434 (52.0%) were the first births.

3.1. Obstetric health outcomes

Regarding first deliveries, induction of labor and elective cesarean section were significantly more common among women with schizophrenia than controls (Table 2). With regard to all pregnancies, induction of labor, as well as deliveries by cesarean section and elective cesarean section were significantly more common among schizophrenic women than controls. Group comparisons related to the studied ICD-10 diagnoses revealed no statistically significant differences.

3.2. Negative perinatal health outcomes of the offspring

Regarding first deliveries, gestational age and birth weight of offspring of women with schizophrenia were significantly lower than those of offspring of control women (Table 3). Also, premature birth, very premature birth, low birth-weight, very low birth-weight, resuscitation, and neonatal monitoring were significantly more common among offspring of schizophrenic women than among offspring of controls. With regard to all pregnancies, the same statistically significant differences were observed, but, in addition to this, low (<7) and very low (<4) Apgar score at 1 min, as well as assisted ventilation were significantly more common among offspring of women with schizophrenia than offspring of controls. Congenital anomalies were significantly more common among offspring of schizophrenic women than offspring of

Table 1
The distribution of background variables among women with schizophrenia and unexposed women

First delivery*	Exposed (n = 753)	Unexposed (n = 2434)	p
Age at birth; mean (SD)	30.1 (5.2)	29.2 (4.3)	<0.001
Cohabiting/married at the end of pregnancy; n (%)	540 (71.7)	2138 (87.8)	<0.001
Smoking in the beginning of pregnancy; n (%)	274 (36.4)	339 (13.9)	<0.001
Sex of the newborn: boy; n (%)	377 (50.1)	1232 (51.0)	0.645
All deliveries*	Exposed (n = 1162)	Unexposed (n = 4683)	p
Age at birth; mean (SD)	30.7 (4.9)	30.4 (4.5)	0.104
Cohabiting/married at the end of pregnancy; n (%)	895 (77.0)	4252 (90.8)	<0.001
Smoking in the beginning of pregnancy; n (%)	408 (35.1)	568 (12.1)	<0.001
Sex of the newborn: boy; n (%)	581 (50.0)	2394 (51.1)	0.494
The number of deliveries; mean (SD)	1.54 (0.85)	1.92 (1.02)	<0.001

The Chi-square (χ^2) test and the independent samples *t*-test (age) were used to compare the groups. The bold values are statistically significant.

* After being diagnosed with schizophrenia.

Table 2
Obstetric complications among women with schizophrenia and among unexposed women.

First delivery ^a	Exposed (n = 753)	Unexposed (n = 2434)	p
Delivery by cesarean section ^a ; n (%)	57 (7.6)	140 (5.8)	0.070
Asphyxia ^b ; n (%)	37 (5.2)	142 (6.1)	0.691
Breech presentation ^b ; n (%)	28 (3.9)	91 (3.9)	0.998
Induction of labor ^b ; n (%)	151 (21.2)	396 (16.9)	0.032
Epidural anesthesia ^b ; n (%)	296 (41.6)	1029 (43.9)	0.543
Use of forceps/vacuum ^a ; n (%)	74 (2.3)	262 (8.2)	0.622
Delivery by elective cesarean section ^b ; n (%)	76 (10.7)	179 (7.6)	0.016
Delivery-related ICD-10 diagnoses ^c ; n (%)			
Fetal distress	32 (8.6)	97 (9.3)	0.072
Maternal distress	6 (1.6)	19 (1.8)	0.486
Rupture of perineum	0 (0.0)	3 (0.3)	0.301
Precipitate labor	0 (0.0)	1 (0.1)	0.551
Prolonged labor	17 (4.6)	32 (3.1)	0.170
Labor and delivery complicated by umbilical cord complications	0 (0.0)	0 (0.0)	1.000
Postpartum hemorrhage	6 (1.6)	27 (2.6)	0.288
Puerperal sepsis	0 (0.0)	3 (0.3)	0.301
Other puerperal infections	0 (0.0)	2 (0.2)	0.399
Puerperal venous complications	0 (0.0)	0 (0.0)	1.000
Obstetric embolism	0 (0.0)	0 (0.0)	1.000
Puerperal psychosis	0 (0.0)	0 (0.0)	1.000
Puerperal depression	1 (0.3)	0 (0.0)	0.093
All deliveries ^a			
Exposed (n = 1162)		Unexposed (n = 4683)	p
Delivery by cesarean section ^a ; n (%)	75 (6.5)	219 (4.7)	0.013
Asphyxia ^b ; n (%)	46 (4.1)	176 (3.8)	0.913
Breech presentation ^b ; n (%)	35 (3.1)	132 (2.9)	0.905
Induction of labor ^b ; n (%)	244 (21.9)	753 (16.5)	< 0.001
Epidural anesthesia ^b ; n (%)	390 (34.9)	1531 (33.5)	0.641
Use of forceps/vacuum ^a ; n (%)	85 (8.2)	317 (7.3)	0.355
Delivery by elective cesarean section ^b ; n (%)	121 (10.4)	355 (7.6)	0.002
Delivery-related ICD-10 diagnoses ^c ; n (%)			
Fetal distress	42 (6.8)	134 (5.8)	0.366
Maternal distress	9 (1.4)	24 (1.0)	0.388
Rupture of perineum	0 (0)	10 (0.4)	0.101
Precipitate labor	0 (0.0)	1 (0.0)	0.604
Prolonged labor	18 (2.9)	45 (1.9)	0.146
Labor and delivery complicated by umbilical cord complications	0 (0.0)	0 (0.0)	1.000
Postpartum hemorrhage	11 (1.8)	53 (2.3)	0.431
Puerperal sepsis	0 (0.0)	3 (0.1)	0.369
Other puerperal infections	0 (0.0)	4 (0.2)	0.300
Puerperal venous complications	0 (0.0)	1 (0.0)	0.604
Obstetric embolism	0 (0.0)	0 (0.0)	1.000
Puerperal psychosis	1 (0.2)	0 (0.0)	0.054
Puerperal depression	1 (0.2)	0 (0.0)	0.054

The Chi-square (χ^2) test, Fisher's exact test and the independent samples t-test (gestational age, birthweight) were used to compare the groups.

The bold values are statistically significant.

^a After being diagnosed with schizophrenia.

^a Recorded since 1987.

^b Recorded since 1991.

^c Recorded since 2004.

controls, for both first deliveries and all deliveries. With regard to different types of congenital anomalies, in first deliveries, syndromes were significantly more frequent among offspring of women with schizophrenia than offspring of controls. When all deliveries were taken into account, both syndromes and isolated anomalies were significantly more frequent among offspring of schizophrenic women than offspring of control women.

3.3. Associations between schizophrenia and obstetric health outcomes

Regarding first deliveries, the risk of induction of labor was 1.3-fold higher in women with schizophrenia (Table 4). With regard to all deliveries, the risk of induction of labor, delivery by cesarean section, and delivery by elective cesarean section was 1.4-fold higher. In adjusted models, all the above-mentioned differences remained statistically significant.

3.4. Associations between maternal schizophrenia and negative perinatal health outcomes of the offspring

Regarding first deliveries, the risk of premature birth, low birthweight (<2500 g), low Apgar score at 1 min (<7), and congenital anomaly ranged from ORs of 1.4 to 1.7 among newborns of women with schizophrenia (Table 5). The risk of resuscitation was 2.7-fold and that of neonatal monitoring 2.5-fold higher. In adjusted models, only differences in the risks of premature birth and neonatal monitoring remained statistically significant. For all deliveries, the risk of premature birth, low birthweight (<2500 g), low Apgar score at 1 min (<7), and congenital anomaly ranged from ORs of 1.3 to 1.8. The risk of very low birth-weight (<1500 g) was 2.0-fold, assisted ventilation 2.2-fold, resuscitation 3.2-fold, and neonatal monitoring 2.4-fold higher. In adjusted models, only risk of premature birth, low Apgar score at 1 min (<7), resuscitation, and neonatal monitoring remained statistically significant.

Table 3

Perinatal health outcomes among offspring of women with schizophrenia and offspring of unexposed women.

First delivery ^a	Exposed (n = 753)	Unexposed (n = 2434)	p
Perinatal death ^a ; n (%)	3 (0.4)	10 (0.4)	0.450
Gestational age ^a (by fetal ultrasound examination at the first maternity care visit); mean (SD)	39.1 (2.26)	39.4 (1.95)	0.002
Premature birth ^a (<37 weeks' gestation); n (%)	56 (7.4)	109 (4.5)	0.003
Very premature birth ^a (<28 weeks' gestation); n (%)	6 (0.8)	12 (0.5)	0.003
Birthweight ^a ; mean (SD)	3401 (625)	3488 (561)	0.001
Low birthweight ^a (<2500 g); n (%)	34 (4.5)	70 (2.9)	0.049
Very low birthweight ^a (<1500 g), n (%)	10 (1.3)	22 (0.9)	0.049
Low Apgar score at 1 min ^a (<7); n (%)	46 (6.1)	116 (4.8)	0.261
Very low Apgar score at 1 min ^a (<4); n (%)	13 (1.7)	34 (1.4)	0.261
Assisted ventilation ^b ; n (%)	11 (1.5)	24 (1.0)	0.253
Resuscitation ^b ; n (%)	14 (2.0)	17 (0.7)	0.004
Neonatal monitoring ^b ; n (%)	159 (22.3)	44 (10.4)	<0.001
Major congenital anomaly ^a ; n (%)	33 (4.4)	89 (3.7)	0.364
type: isolated	21 (2.8)	71 (2.9)	0.059
type: multiple	3 (0.4)	9 (0.4)	0.411
type: syndrome	9 (1.2)	9 (0.4)	0.001
All deliveries ^a	Exposed (n = 1162)	Unexposed (n = 4683)	p
Perinatal death ^a ; n (%)	5 (0.4)	16 (0.3)	0.147
Gestational age ^a (by fetal ultrasound examination at the first maternity care visit); mean (SD)	39.1 (2.22)	39.4 (1.77)	<0.001
Premature birth ^a (<37 weeks' gestation); n (%)	74 (6.4)	184 (3.9)	<0.001
Very premature birth ^a (<28 weeks' gestation); n (%)	10 (0.9)	14 (0.3)	<0.001
Birthweight ^a (grams); mean (SD)	3474 (646)	3560 (541)	<0.001
Low birthweight ^a (<2500 g); n (%)	44 (3.8)	106 (2.3)	0.001
Very low birthweight ^a (<1500 g), n (%)	16 (1.4)	32 (0.7)	0.001
Low Apgar score at 1 min ^a (<7); n (%)	65 (5.6)	165 (3.5)	0.001
Very low Apgar score at 1 min ^a (<4); n (%)	20 (1.7)	51 (1.1)	0.001
Assisted ventilation ^b ; n (%)	18 (1.6)	36 (0.8)	0.011
Resuscitation ^b ; n (%)	19 (1.7)	24 (0.5)	<0.001
Neonatal monitoring ^b ; n (%)	222 (19.9)	413 (9.0)	<0.001
Major congenital anomaly ^a ; n (%)	57 (4.9)	173 (2.9)	0.057
type: isolated	37 (3.2)	137 (2.9)	0.047
type: multiple	6 (0.5)	16 (0.3)	0.161
type: syndrome	14 (1.2)	20 (0.4)	0.001

The Chi-square (χ^2) test, Fisher's exact test and the independent samples t-test (gestational age, birthweight) were used to compare the groups.

The bold values are statistically significant.

^a After being diagnosed with schizophrenia.

^a Recorded since 1987.

^b Recorded since 1991.

3.5. Associations between maternal smoking and negative perinatal health outcomes of the offspring

First, we focused on all women who smoked, with non-smoking women serving as the reference group. Birth year, maternal age, marital status, and parity were used as covariates. With regard to all deliveries, smoking was a significant risk factor for premature birth (OR 1.56, 95% CI 1.16–2.11), low birth-weight (OR 1.41, 95% CI 1.01–1.98), low Apgar score at 1 min (<7) (OR 1.58, 95% CI 1.18–2.13), and neonatal monitoring (OR 2.12, 95% CI 1.75–2.57). Then, we focused on women with schizophrenia who smoked, with non-smoking women with schizophrenia as the reference group. With regard to all deliveries, smoking was a significant risk factor for very low birth weight (OR 3.32, 95% CI 1.14–9.60) and neonatal monitoring (OR 1.50, 95% CI 1.10–2.05) after background adjustment.

3.6. Time trends

Before 2000, the risk of premature birth, very low birth weight (<1500 g), and resuscitation were significantly higher among newborns of women with schizophrenia than newborns of controls. However, during the years 2000 and 2013, this was no longer seen (Table 6). Before 2000, the risk of low Apgar score (1 min; <7) and the risk of congenital anomaly did not differ statistically between newborns of women with schizophrenia and control women, but, after 2000, these risks were significantly higher among newborns of schizophrenic women.

4. Discussion

This register-based, national population study comprised all singleton births among women who were born between 1965 and 1980 and diagnosed with schizophrenia until the end of 2013. We hypothesized schizophrenia to be associated with negative obstetric and perinatal health outcomes, but expected these associations to diminish after adjusting for age, smoking status, and marital status of the mother, as well as for parity and sex of the newborn. Indeed, after adjustment, only the risks of labor induction and delivery by cesarean section remained elevated. Delivery-related ICD-10 diagnoses were rare and, concordant with Hizkiyahu et al. [11], no group differences were observed. In other words, obstetricians seem to use specific delivery methods more often in women with schizophrenia, but delivery-related complications are not increased.

The risk of premature birth, low Apgar score at 1 min (<7), resuscitation and neonatal monitoring were increased. The causes of unwanted perinatal health outcomes and the potential to prevent them remain unclear. Possible causative factors include abnormal fetal development due to a genetic predisposition, the effects of maternal illness and stress, comorbid problems such as sociodemographic disadvantage, poor nutrition and associated life style factors, poor attendance at antenatal care, or the effects of prescribed drugs [20]. We could adjust for some of them, with little influence on our findings.

As a post-hoc analysis, we investigated associations between maternal smoking and unwanted perinatal health outcomes of the

Table 4

The risk of obstetric complications in women with schizophrenia, with control women serving as a reference group.

First delivery [*]	Model	OR (95% CI)
Breech presentation	Crude	1.01 (0.66–1.56)
	Adjusted 1	0.98 (0.62–1.53)
	Adjusted 2	0.98 (0.62–1.53)
Asphyxia	Crude	0.85 (0.59–1.23)
	Adjusted 1	0.75 (0.51–1.12)
	Adjusted 2	0.75 (0.51–1.12)
Epidural anesthesia	Crude	1.10 (0.93–1.30)
	Adjusted 1	0.84 (0.70–1.01)
	Adjusted 2	0.84 (0.70–1.01)
Induction of labor	Crude	1.32 (1.07–1.63) ^a
	Adjusted 1	1.26 (1.01–1.56) ^a
	Adjusted 2	1.26 (1.01–1.56) ^a
Use of forceps/vacuum	Crude	0.91 (0.69–1.19)
	Adjusted 1	0.92 (0.69–1.22)
	Adjusted 2	0.90 (0.69–1.23)
Delivery by cesarean section	Crude	1.06 (0.86–1.32)
	Adjusted 1	1.19 (0.97–1.47)
	Adjusted 2	1.20 (0.97–1.47)
Delivery by elective cesarean section	Crude	1.07 (0.86–1.32)
	Adjusted 1	1.27 (0.94–1.72)
	Adjusted 2	1.27 (0.94–1.72)
Fetal distress	Crude	1.06 (0.71–1.61)
	Adjusted 1	0.96 (0.65–1.42)
	Adjusted 2	0.96 (0.65–1.42)
Prolonged labor	Crude	1.04 (0.67–1.61)
	Adjusted 1	0.96 (0.60–1.54)
	Adjusted 2	0.96 (0.60–1.54)
All deliveries[*]		
Breech presentation	Crude	1.09 (0.75–1.59)
	Adjusted 1	1.03 (0.68–1.54)
	Adjusted 2	1.02 (0.68–1.53)
Asphyxia	Crude	1.07 (0.77–1.50)
	Adjusted 1	0.89 (0.62–1.28)
	Adjusted 2	0.89 (0.62–1.28)
Epidural anesthesia	Crude	1.07 (0.93–1.23)
	Adjusted 1	1.03 (0.75–1.42)
	Adjusted 2	1.03 (0.76–1.41)
Induction of labor	Crude	1.42 (1.21–1.67) ^a
	Adjusted 1	1.38 (1.16–1.65) ^a
	Adjusted 2	1.38 (1.15–1.66) ^a
Use of forceps/vacuum	Crude	1.09 (0.85–1.40)
	Adjusted 1	0.97 (0.74–1.28)
	Adjusted 2	0.97 (0.74–1.28)
Delivery by cesarean section	Crude	1.40 (1.07–1.84) ^a
	Adjusted 1	1.26 (1.04–1.53) ^a
	Adjusted 2	1.26 (1.04–1.53) ^a
Delivery by elective cesarean section	Crude	1.41 (1.14–1.76) ^a
	Adjusted 1	1.37 (1.06–1.77) ^a
	Adjusted 2	1.37 (1.06–1.77) ^a
Fetal distress	Crude	0.79 (0.55–1.12)
	Adjusted 1	1.18 (0.83–1.67)
	Adjusted 2	1.18 (0.83–1.67)
Prolonged labor	Crude	1.62 (0.94–2.81)
	Adjusted 1	1.05 (0.68–1.63)
	Adjusted 2	1.05 (0.68–1.62)
Postpartum hemorrhage	Crude	0.84 (0.44–1.60)
	Adjusted 1	0.73 (0.42–1.27)
	Adjusted 2	0.73 (0.42–1.27)

OR = odds ratio; CI = confidence interval

Results of logistic regression and generalized estimating equation (GEE) models are provided. Maternal age at birth, marital status (single vs. married or cohabitation), parity, and smoking status in the beginning of the pregnancy (yes/no) were used as covariates (Adjusted 1). Next, the previously mentioned variables and sex of the newborn were used as covariates (Adjusted 2).

^{*} After being diagnosed with schizophrenia.

^a Statistically significant finding.

offspring. The stimulus for this emerged from the knowledge that the prevalence of smoking among women, as well as the prevalence of maternal smoking during pregnancy has declined substantially in the Nordic countries during the past twenty years, excluding Finland [21]. Approximately 16% of all Finnish women smoke daily and the steady prevalence of smoking among mothers-to-be is 15% [21].

Table 5

The risk of negative perinatal health outcome among offspring of women with schizophrenia, with control women serving as a reference group.

First delivery [*]	Model	OR (95% CI)
Premature birth	Crude	1.72 (1.25–2.37) ^a
	Adjusted 1	1.54 (1.10–2.17) ^a
	Adjusted 2	1.55 (1.10–2.17) ^a
Low birth-weight (<2500 g)	Crude	1.58 (1.09–2.28) ^a
	Adjusted 1	1.26 (0.89–1.87)
	Adjusted 2	1.25 (0.84–1.86)
Very low birth-weight (<1500 g)	Crude	1.48 (0.70–3.13)
	Adjusted 1	1.08 (0.48–2.42)
	Adjusted 2	1.08 (0.48–2.42)
Low Apgar score at 1 min (<7)	Crude	1.60 (1.07–2.41) ^a
	Adjusted 1	1.26 (0.90–1.75)
	Adjusted 2	1.27 (0.91–1.77)
Very low Apgar score at 1 min (<4)	Crude	1.12 (0.52–2.40)
	Adjusted 1	1.25 (0.63–2.46)
	Adjusted 2	1.26 (0.64–2.48)
Assisted ventilation	Crude	1.52 (0.74–3.11)
	Adjusted 1	1.11 (0.51–2.40)
	Adjusted 2	1.11 (0.51–2.42)
Resuscitation	Crude	2.74 (1.35–5.60) ^a
	Adjusted 1	1.75 (0.81–3.80)
	Adjusted 2	1.75 (0.81–3.80)
Neonatal monitoring	Crude	2.47 (1.98–3.08) ^a
	Adjusted 1	2.02 (1.60–2.55) ^a
	Adjusted 2	2.03 (1.60–2.56) ^a
Major congenital anomaly	Crude	1.42 (1.02–1.98) ^a
	Adjusted 1	1.09 (0.71–1.69)
	Adjusted 2	1.10 (0.71–1.60)
All deliveries[*]		
Premature birth	Crude	1.77 (1.36–2.31) ^a
	Adjusted 1	1.56 (1.16–2.11) ^a
	Adjusted 2	1.57 (1.16–2.11) ^a
Low birth-weight (<2500 g)	Crude	1.79 (1.32–2.44) ^a
	Adjusted 1	1.41 (1.01–1.98) ^a
	Adjusted 2	1.41 (1.01–1.98) ^a
Very low birth-weight (<1500 g)	Crude	2.03 (1.11–3.71) ^a
	Adjusted 1	1.55 (0.82–2.96)
	Adjusted 2	1.55 (0.81–2.97)
Low Apgar score at 1 min (<7)	Crude	1.64 (1.26–2.12) ^a
	Adjusted 1	1.58 (1.18–2.12) ^a
	Adjusted 2	1.60 (1.19–2.15) ^a
Very low Apgar score at 1 min (<4)	Crude	1.60 (0.95–2.69)
	Adjusted 1	1.53 (0.88–2.66)
	Adjusted 2	1.54 (0.88–2.69)
Assisted ventilation	Crude	2.15 (1.23–3.76) ^a
	Adjusted 1	1.81 (0.97–3.39)
	Adjusted 2	1.81 (0.97–3.39)
Resuscitation	Crude	3.23 (1.76–5.91) ^a
	Adjusted 1	2.45 (1.27–4.71) ^a
	Adjusted 2	2.45 (1.28–4.72) ^a
Neonatal monitoring	Crude	2.44 (2.05–2.92) ^a
	Adjusted 1	2.12 (1.75–2.57) ^a
	Adjusted 2	2.13 (1.76–2.58) ^a
Major congenital anomaly	Crude	1.33 (1.04–1.70) ^a
	Adjusted 1	1.31 (0.94–1.82)
	Adjusted 2	1.32 (0.94–1.82)

OR = odds ratio; CI = confidence interval.

Results of logistic regression and generalized estimating equation (GEE) models are provided. Maternal age at birth, marital status (single vs. married or cohabitation), parity, and smoking status in the beginning of the pregnancy (yes/no) were used as covariates (Adjusted 1). Next, the previously mentioned variables and sex of the newborn were used as covariates (Adjusted 2).

^{*} After being diagnosed with schizophrenia.

^a Statistically significant finding.

Smoking turned out to be a risk factor for premature birth, low birth weight, low Apgar score at 1 min (<7), and neonatal monitoring. Thus, our finding agrees with the study by Jacobsen et al. [22] indicating smoking to be one of the greatest risk factors for preterm delivery. Focusing on women with schizophrenia, smoking turned out to be a risk factor for very low birth weight and neonatal monitoring. The self-medication hypothesis [23], common genetic pathways [24], as well as social factors like poverty and low education level [25], have been proposed as an explanation for the

Table 6
The risk of offspring's negative perinatal health outcome among women with schizophrenia in two different time periods, with control women serving as a reference group.

Health outcome; n (%)	All deliveries	Deliveries before 2000	Deliveries between 2000 and 2013
	OR (95% CI)	OR (95% CI)	OR (95% CI)
Premature birth ^a	1.37 (1.16–2.11) ^c	2.49 (1.44–4.30) ^c	1.32 (0.93–1.88)
Low birth-weight (<2500 g) ^a	1.41 (1.01–1.98) ^c	1.37 (0.72–2.59)	1.43 (0.95–2.12)
Very low birth-weight (<1500 g) ^a	1.55 (0.81–2.97)	3.96 (1.49–10.51) ^c	0.97 (0.40–2.32)
Low Apgar score at 1 min (<7) ^a	1.60 (1.19–2.15) ^c	1.66 (0.96–2.88)	1.60 (1.12–2.28) ^c
Very low Apgar score at 1 min (<4) ^a	1.54 (0.88–2.69)	2.22 (0.88–5.63)	1.29 (0.64–2.59)
Assisted ventilation ^b	1.81 (0.97–3.39)	2.81 (0.76–10.35)	1.48 (0.72–3.02)
Resuscitation ^b	2.45 (1.27–4.72) ^c	6.01 (1.32–27.45) ^c	1.96 (0.97–3.97)
Neonatal monitoring ^b	2.13 (1.76–2.58) ^c	2.05 (1.38–3.04) ^c	2.14 (1.72–2.67) ^c
Major congenital anomaly ^a	1.31 (0.94–1.82)	0.95 (0.46–1.95)	1.47 (1.01–2.13) ^c

OR = odds ratio; CI = confidence interval.

Maternal age at birth, marital status (single vs. married or cohabitation), parity, smoking status in the beginning of the pregnancy (yes/no), and sex of the newborn were used as covariates.

^a Recorded since 1987.

^b Recorded since 1991.

^c Statistically significant finding.

strong relationship between nicotine dependency and schizophrenia. However, individuals with schizophrenia are known to be interested in and capable of smoking cessation [26,27]. Our findings underline the need for anti-smoking psychoeducation, as well as targeted smoking cessation interventions for women who plan pregnancy or find out that they are pregnant.

We explored time trends related to the risk of various negative perinatal health outcomes, because of the rising general standard of living, quality of medical care, and decreasing preterm delivery rates among Finnish women [22]. We found that the risk of premature birth and the risk of very low birth weight of the newborn were both significantly higher among women with schizophrenia before 2000, but later this was no longer seen. Recently, Nguyen et al. [28] compared obstetric and neonatal outcomes of a sample of women with severe mental illness, who gave birth between December 2007 and April 2011, with those of the general population. They reported that, in contrast with earlier studies, the risk of preterm birth was not significantly greater compared with controls.

In Finland, approximately 4.8% of newborns have a major congenital anomaly, and this prevalence has remained constant [29]. An unexpected finding was that the risk of congenital anomaly was not significantly elevated among women with schizophrenia before 2000, but was almost 1.5-fold higher in 2000–2013. Given the more advanced currently available screening methods, in cases of recognized anomaly of the fetus, healthy women may induce abortion more often than women with schizophrenia. An important issue is whether our finding could be related to the growing use of atypical antipsychotics [30]. In Finland, the prevalence of typical antipsychotics use was higher than the prevalence of atypical antipsychotics use in 2005, but the finding was the opposite in 2014 [30]. More precisely, according to the national Drug Reimbursement Register (DRR), maintained by the Social Insurance Institution in Finland, the defined daily dose (DDD) of atypical antipsychotics per 1000 inhabitants/day was 3.5 in 1999 and 17.7 in 2013. In a recent study by Huybrechts et al. [31] with more than one million pregnant women, atypical antipsychotics showed no statistically significant risk for congenital malformations (relative risk [RR] 1.05, 95% CI 0.96–1.16). However, a small increased risk in malformations (RR 1.26, 95% CI 1.02–1.56) was found for risperidone. Depression often co-occurs with schizophrenia [32], and the use of antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), has also increased substantially during the last decades [33]. This trend has also been observed in Finland [34]. According to DRR, DDD of SSRIs per 1000 inhabitants/day was

21.4 in 1999 and 41.7 in 2013. Regarding pregnancy, 0.4% of all Finnish pregnant women used SSRI-medication in 1996, but, in 2010, this prevalence was already 3.8% [34]. According to a cohort study with more than 600,000 offspring [35], the overall major congenital anomalies were no more common in SSRI-exposed offspring compared with unexposed ones (OR 1.08, 95% CI 0.96–1.22). However, fluoxetine was associated with an increased risk of isolated ventricular septal defects (OR 2.03, 95% CI 1.28–3.21), paroxetine of right ventricular outflow tract defects (OR 4.68, 95% CI 1.48–14.74), and citalopram of neural tube defects (OR 2.46, 95% CI 1.20–5.07). Overall, to understand more clearly how risks of various perinatal health outcomes vary in time and, especially, to find the clinical relevance from these findings, more time-trend analyses from different countries and cultures are obviously needed.

4.1. Strengths and limitations

The strengths of this study include our ability to investigate the Finnish national female population of patients with schizophrenia or schizoaffective disorder, the relatively long follow-up time, and the high quality of the Finnish health registers [19,36]. Also, the diagnoses of psychotic disorders have been shown to be good [37,38]. However, some limitations need to be considered: first, we used an age- and place-of-birth-matched control group for comparison, but confounding factors such as socioeconomic status were not taken into account. This might have affected birth weight slightly. In Finland, most patients with schizophrenia are on disability pension [39]. However, the municipal health-care services are funded by tax revenues and are available to all citizens regardless of their financial situation or employment. Second, we were limited to variables that were recorded in national registers described earlier. Unfortunately, we had no information about psychotropic or other medications prescribed to women nor the nature and amount of their alcohol or illicit substance use. Moreover, we did not have any paternal information even though this seems to be relevant as well [9]. Third, there may also be differences between individual clinicians and local customs within hospitals in the diagnosis and reporting of ICD-10 diagnoses related to childbirth. Fourth, we assumed that the onset of schizophrenia was the day when the disorder was diagnosed in specialized health-care, but, we had no information before this, for example on the onset and severity of psychiatric symptoms. Finally, considering the high number of outcomes, it must be acknowledged that some of the observed associations may have occurred by chance.

5. Conclusions

Schizophrenia associates with specific delivery methods but delivery complications are rare and their prevalence does not differ from that observed among community women. Maternal schizophrenia associates with some negative perinatal health outcomes of the offspring. Careful monitoring of mothers-to-be with schizophrenia, as well as intense co-operation between psychiatrists, gynecologists and obstetricians are recommended. Anti-smoking psychoeducation, as well as targeted smoking cessation interventions should be offered to schizophrenic women who plan pregnancy or find out that they are pregnant.

Funding sources and their roles

This study has been funded by the Helsinki and Uusimaa Hospital District. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Contributions

LS: study concept and design, collection and interpretation of data, and serving as a first author. EI: study concept and design, and critical revision of the manuscript for important intellectual content. MG: statistical analysis and interpretation of data, and drafting of the manuscript. JS: interpretation of data, and drafting of the manuscript. EH: interpretation of data, and drafting of the manuscript. NL: study concept and design, and interpretation of data, and critical revision of the manuscript for important intellectual content.

Disclosure of interest

The authors declare that they have no competing interest.

Acknowledgement

The authors are most grateful to M. Grainger for her contribution to data management and computational issues.

References

- [1] Solari H., Dickson KE, Miller L. Understanding and treating women with schizophrenia during pregnancy and postpartum –Motherisk Update 2008. *Can J Clin Pharmacol* 2009;16(1):e23–32.
- [2] Vigod SN, Seeman MV, Ray JG, Anderson GM, Dennis CL, Grigoriadis S, et al. Temporal trends in general and age-specific fertility rates among women with schizophrenia (1996–2009): a population-based study in Ontario, Canada. *Schizophr Res* 2012;139(1–3):169–75.
- [3] Sobel DE. Infant mortality and malformations in children of schizophrenic women. *Psychiatr Q* 1961;35:60–5.
- [4] Rieder RO, Rosenthal D, Wender P, Blumenthal H. The offspring of schizophrenics: fetal and neonatal deaths. *Arch Gen Psychiatry* 1975;32:200–11.
- [5] Sacker A, Done DJ, Crow TJ. Obstetric complications in children born to parents with schizophrenia: a meta-analysis of case control studies. *Psychol Med* 1996;26(2):279–87.
- [6] Bennedsen BE, Mortensen PB, Olesen AV, Henriksen TB. Preterm birth and intra-uterine growth retardation among children of women with schizophrenia. *Br J Psychiatry* 1999;175:239–45.
- [7] Bennedsen BE, Mortensen PB, Olesen AV, Henriksen TB, Frydenberg M. Obstetric complications in women with schizophrenia. *Schizophr Res* 2001;47(2–3):167–75.
- [8] Bennedsen BE, Mortensen PB, Olesen AV, Henriksen TB. Congenital malformations: stillbirths, and infant deaths among children of women with schizophrenia. *Arch Gen Psychiatry* 2001;58(7):674–9.
- [9] Nilsson E, Lichtenstein P, Cnattingius S, Murray RM, Hultman CM. Women with schizophrenia: pregnancy outcome and infant death among their offspring. *Schizophr Res* 2002;58(2–3):221–9.
- [10] Jablensky AV, Morgan V, Zubrick SR, Bower C, Yellachich LA. Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. *Am J Psychiatry* 2005;162(1):79–91.
- [11] Hizkiyahu R, Levy A, Sheiner E. Pregnancy outcome of patients with schizophrenia. *Am J Perinatol* 2010;27(1):19–23.
- [12] Matevosyan NR. Pregnancy and postpartum specifics in women with schizophrenia: a meta-study. *Arch Gynecol Obstet* 2011;283(2):141–7.
- [13] Vigod SN, Kurdyak PA, Dennis CL, Gruneir A, Newman A, Seeman MV, et al. Maternal and newborn outcomes among women with schizophrenia: a retrospective population-based cohort study. *BJOG* 2014;121(5):566–74.
- [14] World Health Organization. Manual of the international statistical classification of diseases, injuries, and causes of death. 8th revision Geneva: World Health Organization; 1965.
- [15] American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed., revised. Washington DC: American Psychiatric Press; 1987.
- [16] World Health Organization. Manual of the international statistical classification of diseases, injuries, and causes of death. 9th revision Geneva: World Health Organization; 1977.
- [17] World Health Organization. International statistical classification of diseases and health related problems. 10th revision Geneva: World Health Organization; 1992.
- [18] Gissler M, Teperi J, Hemminki E, Meriläinen J. Data quality after restructuring a national medical registry. *Scand J Soc Med* 1995;23:75–80.
- [19] EUROCAT Central Registry. EUROCAT syndrome guide: definition and coding of syndromes. 2017 version July. www.eurocat-network.eu/aboutus/datacollection/guidelinesforregistration/malformationcodingguides. [Assessed 16 February 2018].
- [20] Judd F, Komiti A, Sheehan P, Newman L, Cast D, Everall I. Adverse obstetrics and neonatal outcomes in women with severe mental illness: to what extent can they be prevented? *Schizophr Res* 2014;157(1–3):305–9.
- [21] Ekblad M, Gissler M, Korkeila J, Lehtonen L. Trends and risk groups for smoking during pregnancy in Finland and other Nordic countries. *Eur J Public Health* 2014;24(4):544–51.
- [22] Jacobsson M, Gissler M, Paavonen J, Tapper AM. The incidence of preterm deliveries decreases in Finland. *BJOG* 2008;115(1):38–43.
- [23] Rütther T, Bobes J, De Hert M, Svensson TH, Mann K, Batra A, et al. EPA guidance on tobacco dependence and strategies for smoking cessation in people with mental illness. *Eur Psychiatry* 2014;29(2):65–82.
- [24] Loukola A, Wedenoja J, Keskitalo-Vuokko K, Broms U, Korhonen T, Ripatti S, et al. Genome-wide association study on detailed profiles of smoking behavior and nicotine dependence in a twin sample. *Mol Psychiatry* 2014;19(5):615–24.
- [25] Tidey JW, Miller ME. Smoking cessation and reduction in people with chronic mental illness. *BMJ* 2015;351:h4065.
- [26] Dickerson F, Stallings CR, Origoni AE, Vaughan C, Khushalani S, Schroeder J, et al. Cigarette smoking among persons with schizophrenia or bipolar disorder in routine clinical settings: 1999–2011. *Psychiatr Serv* 2013;64(1):44–50.
- [27] Gilbody S, Peckham E, Man MS, Mitchell N, Li J, Becque T, et al. Bespoke smoking cessation for people with severe mental ill health (SCIMITAR): a pilot randomised controlled trial. *Lancet Psychiatry* 2015;2(5):395–402.
- [28] Nguyen TN, Faulkner D, Frayne JS, Allen S, Hauck YL, Rock D, et al. Obstetric and neonatal outcomes of pregnant women with severe mental illness at a specialist antenatal clinic. *Med J Aust* 2013;199(3 Suppl):S26–9.
- [29] National Institute for Health and Welfare. Congenital anomalies 2012–2013. National Institute for Health and Welfare; 2017 <http://urn.fi/URN:NBN:fi-fe201706207383>. [Assessed 16 February 2018].
- [30] Hälfðánarson Ó, Zoëga H, Aagaard L, Bernardo M, Brandt L, Fusté AC, et al. International trends in antipsychotic use: a study in 16 countries, 2005–2014. *Eur Neuropsychopharmacol* 2017;10:1064–76.
- [31] Huybrechts KF, Hernández-Díaz S, Paterno E, Desai RJ, Mogun H, Dejene SZ, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. *JAMA Psychiatry* 2016;73(9):938–46.
- [32] Siris SG. Depression in schizophrenia: perspective in the era of Atypical antipsychotic agents. *Am J Psychiatry* 2000;157:1379–89.
- [33] McCarthy M. Antidepressant use has doubled in rich nations in past 10 years. *BMJ* 2013;347:f7261.
- [34] Malm H, Artama M, Brown AS, Gissler M, Gyllenberg D, Hinkka-Yli-Salomäki S, et al. Infant and childhood neurodevelopmental outcomes following prenatal exposure to selective serotonin reuptake inhibitors: overview and design of a Finnish Register-Based Study (FinESS). *BMC Psychiatry* 2012;12:217.
- [35] Malm H, Artama M, Gissler M, Ritvanen A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. *Obstet Gynecol* 2011;118(1):111–20.
- [36] Aro S, Koskinen R, Keskimäki I. Reliability of Hospital Discharge data concerning diagnosis, treatments and accidents. *Duodecim* 1990;106:1443–50.
- [37] Isohanni M, Mäkiyryö T, Moring J, Räsänen P, Hakko H, Partanen U, et al. A comparison of clinical and research DSM-III-R diagnoses of schizophrenia in a Finnish national birth cohort. Clinical and research diagnoses of schizophrenia. *Soc Psychiatry Psychiatr Epidemiol* 1997;32(5):303–8.
- [38] Pihlajamaa J, Suvisaari J, Henriksson M, Heilä H, Karjalainen E, Koskela J, et al. The validity of schizophrenia diagnosis in the Finnish Hospital Discharge Register: findings from a 10-year birth cohort sample. *Nord J Psychiatry* 2008;62(3):198–203.
- [39] Perälä J, Saarni SI, Ostamo A, Pirkola S, Haukka J, Härkänen T, et al. Geographic variation and sociodemographic characteristics of psychotic disorders in Finland. *Schizophr Res* 2008;106(2–3):337–47.